Four cases of disseminated herpes simplex virus following talimogene laherparepvec injections for unresectable metastatic melanoma

Kate E Beekman; Lily M Parker; Danielle K DePalo; Kelly M Elleson; Amod A Sarnaik; Kenneth Y Tsai; Bethany M Withycombe; Jonathan S Zager

doi:10.1016/j.jdcr.2022.12.023

Four cases of disseminated herpes simplex virus following talimogene laherparepvec injections for unresectable metastatic melanoma

JAAD Case Rep. 2023 Jan 27:33:56-58. doi: 10.1016/j.jdcr.2022.12.023. eCollection 2023 Mar.

Authors

Kate E Beekman¹, Lily M Parker¹, Danielle K DePalo², Kelly M Elleson², Amod A Sarnaik^{1

2}, Kenneth Y Tsai³, Bethany M Withycombe⁴, Jonathan S Zager^{1

2}

Affiliations

¹ USF Health, Morsani College of Medicine, Tampa, Florida.
² Department of Cutaneous Oncology, Moffitt Cancer Center, Wesley Chapel, Florida.
³ Department of Anatomic Pathology and Tumor Biology, Moffitt Cancer Center, Wesley Chapel, Florida.
⁴ Department of Pharmacy, Moffitt Cancer Center, Wesley Chapel, Florida.

No abstract available

Keywords: IMLYGIC; T-VEC; acyclovir; adverse events; adverse reactions; dermatology; disseminated herpes infection; drug eruption; drug reactions; drug-induced reactions; herpes encephalitis; herpes simplex virus 1; immunotherapy; intralesional injections; malignant melanoma; melanoma; metastatic melanoma; oncolytic injection; oncolytic virus; regional chemotherapy; regional therapy; skin cancer; surgical oncology; talimogene laherparepvec; valacyclovir; viral dermatitis; viral encephalitis; viral rash.